View source for 3vrm


==Structure of cytochrome P450 Vdh mutant T107A with bound vitamin D3==
<StructureSection load='3vrm' size='340' side='right'caption='[[3vrm]], [[Resolution|resolution]] 2.57&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[3vrm]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Pseudonocardia_autotrophica Pseudonocardia autotrophica]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3VRM OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3VRM FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.57&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=HEM:PROTOPORPHYRIN+IX+CONTAINING+FE'>HEM</scene>, <scene name='pdbligand=VD3:(1S,3Z)-3-[(2E)-2-[(1R,3AR,7AS)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL'>VD3</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3vrm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3vrm OCA], [https://pdbe.org/3vrm PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3vrm RCSB], [https://www.ebi.ac.uk/pdbsum/3vrm PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3vrm ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/CPVDH_PSEAH CPVDH_PSEAH] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Vitamin D3 hydroxylase (Vdh) from Pseudonocardia autotrophica is a cytochrome P450 monooxygenase that catalyzes the two-step hydroxylation of vitamin D3 (VD3 ) to produce 25-hydroxyvitamin D3 (25(OH)VD3 ) and 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2 VD3 ). These hydroxylated forms of VD3 are useful as pharmaceuticals for the treatment of conditions associated with VD3 deficiency and VD3 metabolic disorder. Herein, we describe the creation of a highly active T107A mutant of Vdh by engineering the putative ferredoxin-binding site. Crystallographic and kinetic analyses indicate that the T107A mutation results in conformational change from an open to a closed state, thereby increasing the binding affinity with ferredoxin. We also report the efficient biocatalytic synthesis of 25(OH)VD3 , a promising intermediate for the synthesis of various hydroxylated VD3 derivatives, by using nisin-treated Rhodococcus erythropolis cells containing VdhT107A . The gene-expression cassette encoding Bacillus megaterium glucose dehydrogenase-IV was inserted into the R. erythropolis chromosome and expressed to avoid exhaustion of NADH in a cytoplasm during bioconversion. As a result, approximately 573 mug mL(-1) 25(OH)VD3 was successfully produced by a 2 h bioconversion.

A single mutation at the ferredoxin binding site of p450 vdh enables efficient biocatalytic production of 25-hydroxyvitamin d3.,Yasutake Y, Nishioka T, Imoto N, Tamura T Chembiochem. 2013 Nov 25;14(17):2284-91. doi: 10.1002/cbic.201300386. Epub 2013, Sep 24. PMID:24115473<ref>PMID:24115473</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 3vrm" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Large Structures]]
[[Category: Pseudonocardia autotrophica]]
[[Category: Nishioka T]]
[[Category: Tamura T]]
[[Category: Yasutake Y]]